Quil-A®

Quil-A®

Pharma

Information

Quil-A is a highly purified and concentrated saponin adjuvant purified from bark extract of the Quillaja saponaria Molina tree, which has been specifically developed for use as an adjuvant in vaccines. It consists of a complex mixture of approximately 25 different saponin molecules which have the triterpenoid backbone in common. Quil-A is a very versatile adjuvant due to its ability to induce a balanced immune response to protect against both intracellular (Th1) and extracellular (Th2) pathogens. When combined under specific circumstances with cholesterol, phosphatidylcholine, and amphipathic antigen, saponins can form stable immune stimulating complexes (ISCOMs). These complexes are spherical, nano-scale cage-like structures, which display immune-stimulatory properties. ISCOMs can be used to induce a stronger and longer-lasting immune response.
CrodaCroda International Plc, a specialty chemical company providing high purity and high quality excipients for drug and vaccine development, has recently strengthened their offering with the acquisition of a line of vaccine adjuvants. Providing customers with over 80 years of adjuvant expertise, Croda Vaccine Adjuvants (formerly Brenntag Biosector) has unprecedented industry experience as a vaccine adjuvant specialist. In addition to supplying industry renowned aluminium- and saponin-based adjuvants, including the well-known brands Alhydrogel®, Adju-Phos® and Quil-A®, Croda is committed to developing the next generation of adjuvant technology, with a robust innovation pipeline focusing on enhanced protein binding and immune-stimulating nanotechnology.

Log in